IDIBAPS, Institut d'Investigacions Biomèdiques August Pi i Sunyer

Resultats de l'any: 2010 2009 2008 2007

Articles de l'any 2010

• Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma

  Fernandez V, Salamero O, Espinet B, Sole F, Royo C, Navarro A, Camacho F, Bea S, Hartmann E, Amador V, Hernandez L, Agostinelli C, Sargent RL, Rozman M, Aymerich M, Colomer D, Villamor N, Swerdlow SH, Pileri SA, Bosch F, Piris MA, Montserrat E, Ott G, Rosenwald A, Lopez-Guillermo A, Jares P, Serrano S, Campo E
  CANCER RES. 2010; 70: 1408-1418. IF: 7.543

• Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma

  Mateos MV, Cibeira MT, Richardson PG, Prosper F, Oriol A, DeLaRubia J, Lahuerta JJ, Garcia-Sanz R, Extremera S, Szyldergemajn S, Corrado C, Singer H, Mitsiades CS, Anderson KC, Blade J, SanMiguel J
  CLIN CANCER RES. 2010; 16: 3260-3269. IF: 6.747

• Busulfan 12 mg/kg plus melphalan 140 mg/m(2) versus melphalan 200 mg/m(2) as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study

  Lahuerta JJ, Mateos MV, Martinez-Lopez J, Grande C, DeLaRubia J, Rosinol L, Sureda A, Garcia-Larana J, Diaz-Mediavilla J, Hernandez-Garcia MT, Carrera D, Besalduch J, DeArriba F, Oriol A, Escoda L, Garcia-Frade J, Rivas-Gonzalez C, Alegre A, Blade J, SanMiguel JF
  HAEMATOL-HEMATOL J. 2010; 95: 1913-1920. IF: 6.416

• Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group

  Cervantes F, Lopez-Garrido P, Montero MI, Jonte F, Martinez J, Hernandez-Boluda JC, Calbacho M, Sureda A, Perez-Rus G, Nieto JB, Perez-Lopez C, Roman-Gomez J, Gonzalez M, Pereira A, Colomer D
  HAEMATOL-HEMATOL J. 2010; 95: 1317-1324. IF: 6.416

• Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final resullts of the CSTIBES02 trial

  Ribera JM, Oriol A, Gonzalez M, Vidriales B, Brunet S, Esteve J, DelPotro E, Rivas C, Moreno MJ, Tormo M, Martin-Reina V, Sarra J, Parody R, DeOteyza JP, Bureo E, Bernal MT
  HAEMATOL-HEMATOL J. 2010; 95: 87-95. IF: 6.416

• Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

  Kyle RA, Durie BGM, Rajkumar SV, Landgren O, Blade J, Merlini G, Kroger N, Einsele H, Vesole DH, Dimopoulos M, SanMiguel J, Avet-Loiseau H, Hajek R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson PG, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M
  LEUKEMIA. 2010; 24: 1121-1127. IF: 8.296

• Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective

  Ludwig H, Beksac M, Blade J, Boccadoro M, Cavenagh J, Cavo M, Dimopoulos M, Drach J, Einsele H, Facon T, Goldschmidt H, Harousseau JL, Hess U, Ketterer N, Kropff M, Mendeleeva L, Morgan G, Palumbo A, Plesner T, SanMiguel J, Shpilberg O, Sondergeld P, Sonneveld P, Zweegman S
  ONCOLOGIST. 2010; 15: 6-25. IF: 6.701

• Genetic lesions in chronic lymphocytic leukemia: what's ready for prime time use?

  Moreno C, Montserrat E
  HAEMATOL-HEMATOL J. 2010; 95: 12-15. IF: 6.416

• Novel drugs for the treatment of multiple myeloma

  Blade J, Cibeira MT, Rosinol L
  HAEMATOL-HEMATOL J. 2010; 95: 702-704. IF: 6.416

• Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group

  Oriol A, Vives S, Hernandez-Rivas JM, Tormo M, Heras I, Rivas C, Bethencourt C, Moscardo F, Bueno J, Grande C, DelPotro E, Guardia R, Brunet S, Bergua J, Bernal T, Moreno MJ, Calvo C, Bastida P, Feliu E, Ribera JM
  HAEMATOL-HEMATOL J. 2010; 95: 589-596. IF: 6.416

• International network of cancer genome projects

  Hudson TJ, Anderson W, Aretz A, Barker AD, Bell C, Bernabe RR, Bhan MK, Calvo F, Eerola I, Gerhard DS, Guttmacher A, Guyer M, Hemsley FM, Jennings JL, Kerr D, Klatt P, Kolar P, Kusuda J, Lane DP, Laplace F, Lu YY, Nettekoven G, Ozenberger B, Peterson J, Rao TS, Remacle J, Schafer AJ, Shibata T, Stratton MR, Vockley JG, Watanabe K, Yang HM, Yuen MMF, Knoppers M, Bobrow M, Cambon-Thomsen A, Dressler LG, Dyke SOM, Joly Y, Kato K, Kennedy KL, Nicolas P, Parker MJ, Rial-Sebbag E, Romeo-Casabona CM, Shaw KM, Wallace S, Wiesner GL, Zeps N, Lichter P, Biankin AV, Chabannon C, Chin L, Clement B, DeAlava E, Degos F, Ferguson ML, Geary P, Hayes DN, Johns AL, Nakagawa H, Penny R, Piris MA, Sarin R, Scarpa A, VanDeVijver M, Futreal PA, Aburatani H, Bayes M, Bowtell DDL, Campbell PJ, Estivill X, Grimmond SM, Gut I, Hirst M, Lopez-Otin C, Majumder P, Marra M, Ning ZM, Puente XS, Ruan YJ, Stunnenberg HG, Swerdlow H, Velculescu VE, Wilson RK, Xue HH, Yang L, Spellman PT, Bader GD, Boutros PC, Flicek P, Getz G, Guigo R, Guo GW, Haussler D, Heath S, Hubbard TJ, Jiang T, Jones SM, Li QB, Lopez-Bigas N, Luo RB, Pearson JV, Quesada V, Raphael BJ, Sander C, Speed TP, Stuart JM, Teague JW, Totoki Y, Tsunoda T, Valencia A, Wheeler DA, Wu HL, Zhao SC, Zhou GY, Stein LD, Lathrop M, Ouellette BFF, Thomas G, Yoshida T, Axton M, Gunter C, Mcpherson JD, Miller LJ, Kasprzyk A, Zhang JJ, Haider SA, Wang JX, Yung CK, Cross A, Liang Y, Gnaneshan S, Guberman J, Hsu J, Chalmers DRC, Hasel KW, Kaan TSH, Knoppers BM, Lowrance WW, Masui T, Rodriguez LL, Vergely C, Cloonan N, Defazio A, Eshleman JR, Etemadmoghadam D, Gardiner BA, Kench JG, Sutherland RL, Tempero MA, Waddell NJ, Wilson PJ, Gallinger S, Tsao MS, Shaw PA, Petersen GM, Mukhopadhyay D, Depinho RA, Thayer S, Muthuswamy L, Shazand K, Beck T, Sam M, Timms L, Ballin V, Ji JF, Zhang XQ, Chen F, Hu XD, Yang Q, Tian G, Zhang LH, Xing XF, Li XH, Zhu ZG, Yu YY, Yu J, Tost J, Brennan P, Holcatova I, Zaridze D, Brazma A, Egevad L, Prokhortchouk E, Banks RE, Uhlen M, Viksna J, Ponten F, Skryabin K, Birney E, Borg A, Borresen-Dale AL, Caldas C, Foekens JA, Martin S, Reis-Filho JS, Richardson AL, Sotiriou C, Van'tVeer L, Birnbaum D, Blanche H, Boucher P, Boyault S, Masson-Jacquemier JD, Pauporte I, Pivot X, Vincent-Salomon A, Tabone E, Theillet C, Treilleux I, Bioulac-Sage P, Decaens T, Franco D, Gut M, Samuel D, Zucman-Rossi J, Eils R, Brors B, Korbel JO, Korshunov A, Landgraf P, Lehrach H, Pfister S, Radlwimmer B, Reifenberger G, Taylor MD, VonKalle C, Majumder PP, Pederzoli P, Lawlor RT, Delledonne M, Bardelli A, Gress T, Klimstra D, Zamboni G, Nakamura Y, Miyano S, Fujimoto A, Campo E, DeSanjose S, Montserrat E, Gonzalez-Diaz M, Jares P, Himmelbaue H, Bea S, Aparicio S, Easton DF, Collins FS, Compton CC, Lander ES, Burke W, Green AR, Hamilton SR, Kallioniemi OP, Ley TJ, Liu ET, Wainwright BJ
  NATURE. 2010; 464: 993-998. IF: 34.48

• Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma

  Palumbo A, Davies F, Kropff M, Blade J, Delforge M, DaCosta FL, Sanz RG, Schey S, Facon T, Morgan G, Moreau P
  ANN HEMATOL. 2010; 89: 803-811. IF: 2.919

• Guidelines for the use of bisphosphonates in multiple myeloma: Recommendations of the expert committee of the Spanish Myeloma Group from the PETHEMA group

  Garcia-Sanz R, Alegre A, Capote FJ, Hernandez JM, Rosinol L, DeLaRubia J, Sureda A, DeArriba F, Bargay J, Mediavilla JD, Garcia-Larana J, Lahuerta JJ, Mateos MV, Prosper F, Miguel JS, Blade J
  MED CLIN-BARCELONA. 2010; 134: 268-278. IF: 1.231

Més articles

Tesis

• Estudi del fenomen de la transformació histològica en síndromes limfoproliferatives indolents

  Doctorand: Eva Giné Soca,
  Director/s: Bosch F

• Vacunas con células dendríticas y pépticos en el tratamiento de las enfermedades neoplásicas

  Doctorand: Marta Gomez Nuñez,
  Director/s: Cervantes F